April 4, 2018 07:00 AM EDT

Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup

John Carroll

Editor & Founder

Nearly 4 years after Roche agreed to pay the research tab for a team of investigators at Versant Ventures’ discovery group Inception Sciences to see …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup

John Carroll

Editor & Founder

Sign up to read this article for free.

‘Just the beginning’: Nobel Prizes show the AI era has arrived in biotech

Exclusive Q&A: FDA's principal deputy commissioner on taking over for Califf, adcomms, accelerated approvals and more

CMS looks to $2 out-of-pocket cap for some commonly used generic drugs

AI biotech insitro partners with Lilly on metabolic disease drugs

Zealand Pharma hit with second CRL for glucagon receptor agonist

GSK to pay up to $2.2B to settle almost all Zantac-related court cases

Roche grabs a re­myeli­na­tion MS drug from Ver­sant as the re­search team spins out in­to a $25M re­gen­er­a­tive med start­up

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

Zealand Phar­ma hit with sec­ond CRL for glucagon re­cep­tor ag­o­nist

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup

‘Just the beginning’: Nobel Prizes show the AI era has arrived in biotech

Exclusive Q&A: FDA's principal deputy commissioner on taking over for Califf, adcomms, accelerated approvals and more

CMS looks to $2 out-of-pocket cap for some commonly used generic drugs

AI biotech insitro partners with Lilly on metabolic disease drugs

Zealand Pharma hit with second CRL for glucagon receptor agonist

GSK to pay up to $2.2B to settle almost all Zantac-related court cases